Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial by Veenstra-VanderWeele, Jeremy, Cook, Edwin H, King, Bryan H, Zarevics, Peter, Cherubini, Maryann, Walton-Bowen, Karen, Bear, Mark, Wang, Paul P, Carpenter, Randall L

Get full text

Arbaclofen in fragile X syndrome: results of phase 3 trials by Berry-Kravis, Elizabeth, Hagerman, Randi, Visootsak, Jeannie, Budimirovic, Dejan, Kaufmann, Walter E., Cherubini, Maryann, Zarevics, Peter, Walton-Bowen, Karen, Wang, Paul, Bear, Mark, Carpenter, Randall L

Get full text
Get full text

Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial by Berry-Kravis, Elizabeth M., Hessl, David, Rathmell, Barbara, Zarevics, Peter, Cherubini, Maryann, Walton-Bowen, Karen, Mu, Yi, Nguyen, Danh V., Gonzalez-Heydrich, Joseph, Wang, Paul P., Carpenter, Randall L., Hagerman, Randi J., Bear, Mark

Get full text

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study by Erickson, Craig A., Veenstra-Vanderweele, Jeremy M., Melmed, Raun D., McCracken, James T., Ginsberg, Lawrence D., Sikich, Linmarie, Scahill, Lawrence, Cherubini, Maryann, Zarevics, Peter, Walton-Bowen, Karen, Carpenter, Randall L., Wang, Paul P., King, Bryan H., Bear, Mark

Get full text